AbbVie Inc (ABBV)vsMedpace Holdings Inc (MEDP)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
MEDP
Medpace Holdings Inc
$587.52
+0.75%
HEALTHCARE · Cap: $16.49B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2214% more annual revenue ($64.39B vs $2.78B). MEDP leads profitability with a 17.7% profit margin vs 9.8%. ABBV appears more attractively valued with a PEG of 0.52. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
MEDP
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Margin of Safety
-39.2%
Fair Value
$304.57
Current Price
$587.52
$282.95 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Every $100 of equity generates 113 in profit
Conservative balance sheet, low leverage
Strong operational efficiency at 20.8%
17.2% revenue growth
Earnings expanding 37.1% YoY
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Premium valuation, high expectations priced in
Grey zone — moderate risk
Expensive relative to growth rate
Trading at 37.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : MEDP
The strongest argument for MEDP centers on Return on Equity, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 20.8%. Revenue growth of 17.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : MEDP
The primary concerns for MEDP are P/E Ratio, Altman Z-Score, PEG Ratio.
Key Dynamics to Monitor
ABBV profiles as a value stock while MEDP is a growth play — different risk/reward profiles.
MEDP carries more volatility with a beta of 1.15 — expect wider price swings.
MEDP is growing revenue faster at 17.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 68/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Medpace Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?